Emma Guttman, MD
- PROFESSOR | Dermatology
- PROFESSOR | Medicine, Clinical Immunology
Emma Guttman-Yassky, MD, PhD is a Professor of Dermatology & Immunology and Director of the center for Excellence in Eczema , the Occupational/Contact Dermatitis clinic, and the Director of the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center in New York. She earned her M.D. degree from Sackler School of Medicine at the Tel-Aviv University, and a Ph.D. degree from the Bar-Ilan University Ramat-Gan, Israel. Dr. Guttman completed her first dermatology residency at the Dermatology Department at the Rambam Medical Center/Technion Institute in Haifa. After obtaining her Israeli Board certification in dermatology, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after obtaining her second dermatology residency training at the Weill-Cornell Medical College, in NY. Dr. Guttman’s major clinical focus is atopic dermatitis (AD)/eczema, contact/occupational dermatitis, alopecia areata, and psoriasis. She has done groundbreaking research and published extensively on inflammatory skin diseases. Her research made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis (AD) in humans, enriching the understanding of the pathophysiology of this common disorder, opening the door to new therapeutics. Dr. Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of disease- and response- biomarkers that are now accelerating testing of novel immune, pathway-specific drugs in this disease. Her research is the first to identify in humans a distinct population of T-cells that independently produce IL-22, conceptualizing AD as a Th2/Th22-polarized disease. Dr Guttman is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets. Together with Dr. Amy Paller she founded the international eczema council (IEC), for which she functions as president elect. Dr Guttman was (2015) elected as a member to the American Society for Clinical Investigation (ASCI), as well as the American Dermatological Society (ADA), and is the recipient of the prestigious Young Investigator Award (2011) from the American Academy of Dermatology (AAD). She also received the Dermatology Foundation’s Physician-Scientist Career Development Award, and the Everett C. Fox Award for best clinical research at the Residents & Fellows Symposium of the AAD. Dr. Guttman has been awarded several federal and foundation grants. She received a large NIH grant to do a proof of concept study on the role of Th22 T-cells in atopic dermatitis/eczema using a novel anti IL-22 antibody. She has also secured a grant from the LEO Foundation to study immune and terminal differentiation biomarkers in pediatric AD, as well as an
award from the National Institute of Allergy and Infectious Diseases (NIAID)
to participate in a multi-center study on the role of infections in AD.
Additionally, she received support from pharmaceutical companies, underscoring her recognition as an outstanding physician-scientist in the dermatology community. She is doing many mechanistic studies involving clinical trials with new therapeutics in patients atopic dermatitis around the globe. Her research on eczema has contributed directly to the recently developed treatments for this disease, earning her a unique place in dermatology and immunology worldwide. She is now invited to speak and chair symposia not only nationally, but also in Europe and Japan on novel developments in AD and its therapeutics.
American Board of Dermatology
- Allergy Testing
- Alopecia Areata
- Atopic Dermatitis
- Clinical Trials
- Contact Dermatitis